OSLO /LONDON ,APRIL 20th 2021 :EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced that it has been selected as the Norwegian flagship company at the Nordic Life Science ("NLS") days conference with CEO, DrRafiq Hasan , participating in the opening plenary. NLS Days is the largest Nordic partnering conference dedicated to the life science industry and is taking placeApril 20-23 . "It is a privilege to be selected as the flagship company fromNorway at the NLS Days 2021 meeting alongside other great Nordic companies", said DrRafiq Hasan , CEO ofEXACT Therapeutics AS . "NLS Days 2021 is a great opportunity to learn about the strong innovation emerging from the Nordic region, as well as to share experiences and best practices. The conference comes at an exciting time for the Company with our ongoing Phase I ACTIVATE study, continued expansion in bothNorway and theUK with key appointments, the opening of a new research facility and expanding technology collaboration withGE Healthcare ." About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes. About EXACT-Tx EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com For more information contact: DrRafiq Hasan , CEO EXACT Therapeutics Rafiq@exact-tx.com
Click here for more information
© Oslo Bors ASA, source